Skip to main content

Yellow fever vaccine Disease Interactions

There are 2 disease interactions with yellow fever vaccine.

Major

Vaccination (applies to yellow fever vaccine) infections

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Typhim VI (typhoid vaccine, inactivated)." Apothecon Inc (2022):
  2. "Product Information. Varivax (varicella virus vaccine)." Merck & Company Inc (2022):
  3. "Product Information. Pneumovax 23 (pneumococcal 23-polyvalent vaccine)." Merck & Company Inc (2022):
  4. "Product Information. Mumpsvax (mumps virus vaccine)." Merck & Company Inc (2022):
  5. "Product Information. Meruvax II (rubella virus vaccine)." Merck & Company Inc (2022):
  6. "Product Information. Attenuvax (measles virus vaccine)." Merck & Company Inc (2022):
  7. "Product Information. Orimune (poliovirus vaccine, live, trivalent)." Lederle Laboratories (2022):
  8. "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur (2001):
  9. "Product Information. Omnihib (haemophilus b conjugate vaccine (obsolete))." SmithKline Beecham
  10. "Product Information. Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught Laboratories Inc
  11. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc (2001):
  12. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases." Grove Village, IL: American Academy of Pediatrics (1997):
  13. "Product Information. Cholera Vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories
  14. "Product Information. Havrix (hepatitis A adult vaccine)." SmithKline Beecham
  15. "Product Information. Engerix-B (hepatitis B adult vaccine)." Apothecon Inc (2022):
  16. "Product Information. Zostavax (zoster vaccine live)." Merck & Company Inc (2006):
  17. "Product Information. Gardasil (human papillomavirus vaccine)." Merck & Company Inc (2006):
  18. "Product Information. Gardasil 9 (human papillomavirus vaccine)." Merck & Company Inc (2016):
View all 18 references
Major

Yellow fever vaccine (applies to yellow fever vaccine) immunodeficiency

Major Potential Hazard, High plausibility.

In general, the use of yellow fever vaccine is contraindicated in patients with primary or acquired immunodeficiency. Since yellow fever vaccine contains live attenuated virus, the absence of immune competence may potentiate the replication of vaccine virus, increase adverse host reactions, and compromise serum antibody response. In patients with severe immunosuppression or known HIV infection, the use of yellow fever vaccine may pose a theoretical risk of encephalitis. Asymptomatic HIV-infected patients may be vaccinated if potential exposure to yellow fever virus is deemed unavoidable. However, they should be monitored for adverse effects, and it may be necessary to have neutralizing antibody titers obtained before departure to gauge the adequacy of the serum antibody response. Finally, the vaccine should not be administered to anyone with a family history of congenital or hereditary immunodeficiency until the individual's immune status can be assessed and is determined to be adequate.

References

  1. "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur (2001):

Yellow fever vaccine drug interactions

There are 281 drug interactions with yellow fever vaccine.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.